NCT05145413已完成3 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company327 个研究点 分布在 1 个国家目标入组 396 人开始时间: 2021年11月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 396
- 试验地点
- 327
- 主要终点
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
研究概览
简要总结
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is aged ≥18 to <65 years at the time of randomization
- •Subject is capable of providing signed Informed Consent Form before any study assessments will be performed
- •Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2
- •Subject is currently being treated with stable dosing of monotherapy risperidone, paliperidone, aripiprazole, or their LAIs ziprasidone, lurasidone, or cariprazine and has been taking this treatment with the same dosing regimen for at least 8 weeks at the time of Day 1 (Visit 3)
- •The subject has had at least 1 previous inadequate response to above antipsychotics that was dosed appropriately (within the label) for at least 6 weeks
- •The subject has not required psychiatric hospitalization, incarceration in prison, acute crisis intervention, or other increase in the level of care due to symptom exacerbation within 8 weeks of Screening and is psychiatrically stable in the opinion of the Investigator
- •To be eligible for randomization, subjects need to have detectable levels of background antipsychotic medication (measured at Visit 1)
- •Positive and Negative Syndrome Scale (PANSS) total score ≥ 70 at Screening and randomization
- •Clinical Global Impression-Severity (CGI-S) scale with a score ≥ 4 (moderate) at Screening and randomization
- •PANSS Marder Positive symptom factor ≥ 4 on 2 (or more) items (PANSS items, delusions, hallucinations, grandiosity, suspiciousness and persecution, stereotyped thinking, somatic concern, unusual thought content or lack of judgment and insight), at Screening and randomization
- •Subjects with ≤ 20-point decrease in PANSS Total score between Visit 1 and Visit 3
- •Subject is willing and able to visit the clinic in an outpatient setting for the study duration, follow instructions, and comply with the protocol requirements
- •Body Mass Index (BMI) must be within 18 to 40 kg/m2 (inclusive of both values)
- •Subject resides in a stable living situation in the opinion of the Investigator
- •Subject has identified a reliable informant/ caregiver willing and able to assist with study activities as needed throughout the subject's participation in the study. The informant needs to be physically present at the Baseline visit, but can complete the remaining study visits assessments via phone (as needed and as per local regulations). In Bulgaria, the informant needs to physically present at the Baseline visit and should be physically present at all study visits where the Investigator determines that his/her input would be beneficial.
- •Women of childbearing potential (WOCP), or men whose sexual partners are WOCP, must be able and willing to use at least 1 highly effective method of contraception during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of the study drug. A female subject is considered to be a WOCP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)
排除标准
- •Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening)
- •The subject has a history of moderate to severe substance use disorder (other than nicotine) within the past 12 months
- •A Screening subject with mild substance use disorder within the 12 months before Screening must be discussed with the Medical Monitor before being allowed into the study
- •Subjects who test positive for cannabis at Screening may be permitted to enroll in consultation with the Medical Monitor if the subject's pattern of use is not indicative of a moderate to severe substance use disorder
- •Subject has a history of treatment-resistant schizophrenia defined as:
- •a. Failure to minimally respond to 2 adequate courses of antipsychotic drug (APD) pharmacotherapy Note: Failure to minimally respond is defined as persistence symptoms of moderate severity in 2 or more psychotic symptom domains or persistence of severe symptoms in 1 or more psychotic symptom domains despite adequate dose and duration (6 weeks or longer) of APD treatment.
- •History of symptom instability
- •a. > 3 psychiatric hospitalizations over the last 12 months or 2 over the last 6 months
- •Current APD is other than aripiprazole, risperidone, paliperidone, or their LAI versions, ziprasidone, lurasidone, or cariprazine
- •Subjects who are diagnosed with schizophreniform disorder or are experiencing their first treated episode of schizophrenia
- •Significant or severe medical conditions including pulmonary, cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject or the validity of the study results
- •eGFR < 60 mL/min
- •Alanine transaminase or aspartate transaminase (AST) > 1.5 x upper limit of normal (ULN)
- •Total bilirubin > 1.5 x ULN (Subjects with Gilbert's syndrome can be included as long as direct bilirubin is ≤ 1.5 x ULN)
- •Subjects with human immunodeficiency virus (HIV), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections as indicated by medical history, serologies or LFT results
- •History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator
- •History of irritable bowel syndrome (with or without constipation) or any serious constipation requiring treatment within the last 6 months
- •Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSRS as confirmed by the following:
- •Answers "Yes" on items 4 or 5 (C-SSRS - ideation) with the most recent episode occurring within the 2 months before Screening or,
- •Answers "Yes" to any of the 5 items (C-SSRS behavior) with an episode occurring within the 12 months before Screening
- •Clinically significant abnormal finding on the physical examination, medical history, ECG, or clinical laboratory results at Screening
- •Urine toxicology screen is positive for phencyclidine, amphetamines, opiates, cocaine, or alcohol (clinically significant alcohol use in the opinion of the Investigator)
- •Subject is currently taking, or plans to take while in the study, any prohibited concomitant medication.
- •Pregnant, lactating, or less than 3 months postpartum
- •If, in the opinion of the Investigator and/or Sponsor/Medical Monitor subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator and/or Sponsor/Medical Monitor, may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements
- •Positive test for coronavirus (COVID-19) within 2 weeks or at Screening
- •Subjects with extreme concerns relating to global pandemics, such as COVID-19, that would obscure ratings or be expected to disrupt adherence to trial procedures
- •Unable to taper and discontinue a concomitant medication that would preclude participation in the double-blind adjunctive treatment (e.g., cannot stop anticholinergic)
- •Subjects with prior exposure to KarXT
- •Subjects who experienced any adverse effects due to xanomeline or trospium
- •Subjects who received investigational product as part of a clinical trial within 3 months of Screening
- •Risk of violent or destructive behavior as per Investigator's judgment that would interfere with subject's participation
- •Current involuntary hospitalization or incarcerationor on parole/probation
- •For all male subjects only, any one of the following:
- •History of bladder stones
- •History of recurrent urinary tract infections
- •Serum prostate specific antigen (PSA) >10 ng/mL
- •An International Prostate Symptom Score (IPSS) of 5 (almost always) on either item 1, 3, 5, or 6
- •A sum of scores on IPSS items 1, 3, 5, and 6 of ≥9 Note: IPSS will be required only for male subjects ≥ 45 years of age. Subjects already enrolled in the study will have these assessments at their next clinic visit planned after re-consenting to determine current eligibility.
研究组 & 干预措施
Drug: KarXT
Experimental
干预措施: Xanomeline and Trospium Chloride Capsules (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
时间窗: Week 6
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
次要结局
- Change from Baseline in Personal Social Performance (PSP) at Week 6(Week 6)
- Change from Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6(Week 6)
- Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Positive symptom factor score at Week 6(Week 6)
- Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Negative symptom factor score at Week 6(Week 6)
- Categorical response defined as the proportion of subjects achieving a ≥ 30% improvement in PANSS total score at Week 6(Week 6)
- Preference of Medication (POM) at Week 6(Week 6)
研究者
研究点 (327)
Loading locations...
相似试验
已完成
3 期
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea PedisTinea PedisNCT01290341Merz North America, Inc.860
招募中
3 期
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Psychosis Associated With Alzheimer's DiseaseNCT05511363Karuna Therapeutics, Inc., a Bristol Myers Squibb company410
已完成
3 期
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)Major Depressive DisorderNCT04688164Relmada Therapeutics, Inc.227
已完成
3 期
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)Major Depressive DisorderNCT05081167Relmada Therapeutics, Inc.232
终止
3 期
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)Major Depressive DisorderDepressionNCT04855747Levomecor Inc.236